Skip to main content
Premium Trial:

Request an Annual Quote

Luxembourg Cancer Institute Launches Precision Oncology Study

NEW YORK (GenomeWeb) — Luxembourg's Institut National du Cancer (INC) announced today that it has begun an initiative to evaluate the use of molecular diagnostics in cancer treatment.

Called MDLUX2, the three-year program — which is being sponsored by the Fondation Cancer, the Fondatioun Kriibskrank Kanner, and Integrated BioBank of Luxembourg (IBBL) — will use a standardized set of molecular diagnostics to analyze tissue samples from hundreds of cancer patients recruited through local hospitals. The resulting data will be used to characterize the mutations driving patients' tumors and inform treatment decisions.

"The project seeks to guide clinicians in their choice of the most appropriate treatment to be administered to each individual patient," INC Coordinator Nikolai Goncharenko said in a statement. "Our goal is to improve clinical outcomes for patients whilst strengthening Luxembourg's position with respect to molecular diagnostics, personalized medicine, and cancer research."

Belgian precision medicine firm OncoDNA will provide molecular diagnostic services and its OncoKDM data interpretation and reporting platform to MDLUX2. Remaining tissue and associated clinical data will be stored at IBBL and made available for future research, pending patient consent.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.